Lonza Group AG (LONN.SW) Zen Horizon Research Report

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?6/10

  A

  Conclusion first: the ceiling is high enough and the runway is long enough, but Lonza is taking a larger share of an existing pie that is growing quickly, not creating an entirely new market. Its business is biologics contract development and manufacturing (CDMO). Demand is driven by drug molecules invented by others. Lonza does not create new therapies or new end markets itself. This fits the "long runway" Baillie Gifford values most, but it sits closer to the "existing pie" end of the spectrum.

  The pie itself is expanding rapidly. Global biologics CDMO is a structurally growing market: antibodies, ADCs, bispecifics, and cell and gene therapies, the "hard-to-make large molecules," are increasingly outsourced to third-party manufacturers. The industry generally expects mid-to-high single-digit to double-digit compound growth over the next decade. Lonza's own 2026 full-year guidance calls for 11–12% sales growth at constant exchange rates and a Core EBITDA margin above 32%, while its medium-term "One Lonza" strategy anchors CDMO annual growth at 11–13%. That number itself shows the company believes penetration headroom remains large, rather than already capped out.

  The ceilings in its two favored subsegments are indeed rising. ADCs (antibody-drug conjugates) are the hottest new oncology modality. Global ADC sales were about USD 12.2–12.3 billion in 2024, with several institutions forecasting a rise to the USD 25–33 billion range by the mid-2030s (the report text's "USD 14 B→40 B+" is aggressive at both ends; a more prudent framing is about 12 billion→25–30 billion). Lonza's Visp site in Switzerland is one of the few global bases able to handle commercial ADC outsourcing, so it is capturing this incremental demand. Large-scale mammalian capacity is another scarce lane.

  But the honest framing is this: Lonza is penetrating existing demand, not opening up new demand. Whether a pharmaceutical company develops a given monoclonal antibody or ADC is decided by that company's R&D and regulators. How much Lonza captures depends on its capacity, geopolitical trust, and switching costs, not on its ability to conjure a market that did not exist before. Compared with disruptive growth companies that create entirely new markets, its upside is more predictable and more constrained by customer pipelines. The ceiling is high, but the growth rate is capped in the mid-teens. That needs to be distinguished from companies that truly create new categories.

  The Baillie Gifford takeaway: The long runway is real: the biologics outsourcing megatrend, ADCs, and scarce large-scale capacity all deserve high marks. But because this is about growing an existing pie rather than creating a new market, its growth imagination is that of a high-quality picks-and-shovels annuity collector, not an exponential breakout. This is steady growth from taking share in a good lane, not an unlimited-ceiling disruptor.

  Jun 10, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?5/10

  A

  Conclusion first: doubling revenue over the next five years (about 15% CAGR) is a high bar and is unlikely on the company's own guidance. A more realistic outcome is about 70–90% growth over five years (11–13% CAGR). Growth is driven mainly by volume: ramping utilization of new capacity plus newly signed commercial contracts. Price is secondary, and "new business" is a structural catalyst but not the main engine.

  Start with the base. Lonza's 2025 sales were CHF 6.5 B, up 21.7% year on year at constant exchange rates (that year included consolidation of Vacaville and concentrated ramp-up from new commercial contracts, so it was an elevated year). The company's 2026 full-year guidance is 11–12% sales growth at constant exchange rates and a Core EBITDA margin above 32%, while the medium-term "One Lonza" strategy anchors CDMO annual growth at 11–13%. At 11–13% compounded for five years, revenue rises only about 70–85%, short of a strict "doubling." Doubling would require a CAGR≈15% for five consecutive years, 2 percentage points above the top of management guidance, and would require BIOSECURE benefits, full Vacaville utilization, and ADC upside all to overdeliver together. That cannot be the default assumption.

  An important reporting-basis reminder: the revenue base is about to get smaller. In March 2026, Lonza announced that it would sell Capsules & Health Ingredients (CHI, about 30% of the former group's revenue) to Lone Star for EV CHF 2.3 B, retain a 40% stake, close in H2 2026, and formally transform into a pure-play biologics CDMO. That means once the disposal closes, absolute reported revenue will first "shrink" by about 30%, then grow faster from a smaller pure CDMO base. The report text still treats CHI as a core business in hand, which is outdated. Any "doubling" analysis has to use the post-disposal pure CDMO base, or it will be distorted by a one-off balance-sheet contraction.

  Growth breaks into three pieces, with volume the main driver:

  • Volume (main engine): utilization ramp-up after integrating the 330,000 L Vacaville capacity in California, plus newly signed Phase II/III commercial outsourcing contracts ramping by kilograms. CDMO growth is fundamentally "capacity comes online→utilization climbs from low levels to full capacity," a classic volume-driven model.
  • Price (secondary): the large-scale mammalian-capacity "duopoly" gives Lonza some pricing and reservation-fee leverage, but pricing elasticity is limited and is not the main driver.
  • New businesses (catalysts, not the core engine): ADCs, bispecifics, and CGT taking over, plus US customers redirecting orders under the BIOSECURE Act. Lonza's North America growth in 2025 was meaningfully above the group average. This is an upside option, but realization depends on how forcefully policy is implemented.

  The Baillie Gifford takeaway: "Doubling in five years" is Baillie Gifford's hard test for true growth. Lonza can credibly deliver double-digit organic growth, driven by volume with high visibility, and the quality is good. But a strict doubling requires overdelivery beyond guidance, with a probability that is medium-low. It deserves strong credit for "solid double-digit growth," but a discount to "inevitable doubling." This is a steady compounder, not a definite doubler.

  Jun 10, 2026
• QAfter five years, what will take over as the next growth engine? Does this "second curve" exist today?4/10

  A

  Conclusion first: the second curve already exists today and is loading. It is centered on specialized ADC (antibody-drug conjugate) capacity plus large-scale mammalian capacity (Vacaville), while cell and gene therapy (CGT) and bispecifics are a later third curve. But be clear: these successors are still extensions of the same CDMO business, new therapy categories under the same outsourcing model. They are the next segment of the main curve, not a truly heterogeneous new growth pole.

  The handoff starts from the fact that the first curve, mRNA/Moderna, has burned out. In 2020–2022, Lonza's largest growth engine was manufacturing COVID mRNA vaccines for Moderna, with peak annual revenue from a single customer of about CHF 1.5 B (about 25% of the group). After contract renegotiation in 2023–2024, the business fell to a steady state of about CHF 300–400 M. That was the largest "curve collapse" of the past several years. Precisely because Lonza lived through the fading of a single blockbuster, "who takes over next" is not theoretical for the company; it is a real requirement already under way. That makes the answer more credible.

  The second curves loading today:

  • Specialized ADC capacity: only 3–4 CDMOs globally can handle commercial ADC outsourcing. The ADC market was about USD 12.2 billion in 2024 and is expected to rise to the USD 25–30 billion range by the mid-2030s (the text's "40 B+" is aggressive). Lonza's Visp site is one of the largest single sites. This is the clearest and nearest successor.
  • Large-scale mammalian capacity: in 2024 Lonza acquired Roche's Vacaville site for USD 1.2 B (California, 330,000 L), doubling commercial capacity and locking in a long-tail annuity for the next 10–15 years. This is the volume second curve.

  The later third curve: CGT (cell and gene therapy), bispecific antibodies, and non-vaccine mRNA applications. These represent capacity bookings for newer therapy modalities, but commercial realization lies further out; today they are more about planting seeds.

  The honest limitation: successors are not a true second curve; they are the next segment of the same engine. ADCs, CGT, and bispecifics are still "hard-to-make large molecules invented by others, outsourced to Lonza." The business model, funnel annuity, milestone/kilogram pricing, and BLA lock-in are identical to the first curve. What changes is the category of the outsourced product, not the business. This differs from companies that use a cash cow to incubate a new business with a logic different from the core. Lonza's regenerative capacity comes from "distributed capture of the R&D pipeline" (participating broadly across the industry's new therapies). Any one new modality can take over if it breaks out, but the form of that handoff remains outsourcing.

  The Baillie Gifford takeaway: Baillie Gifford wants to see whether "the next engine five years from now is visible today." Lonza qualifies: ADC and large-scale capacity are real, in hand, and quantifiable successors. After the mRNA fade, management has explicitly put "growth without Moderna" into the medium-term baseline, proving this is not fragile growth from a single blockbuster. It earns a relatively high score for "the second curve is clearly visible," but loses the imagination premium for "truly rebuilding a new business," because the successor is an extension of the main curve rather than a heterogeneous new pole.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Conclusion first: the core moat is the triple overlap of extremely high customer switching costs from BLA regulatory lock-in, a "duopoly" in large-scale mammalian capacity above 200,000 L, and scarce ADC process complexity. Over the next three to five years it will probably "remain wide and tilt wider." BIOSECURE implementation and capacity scarcity are widening forces, but Samsung Biologics' aggressive expansion is real narrowing pressure. This is a wide moat with a close rival chasing hard, not an unassailable monopoly.

  Verify the moat sources one by one:

  • BLA regulatory lock-in (hardest): once a biologic's production process, site, and raw-material chain are written into FDA approval files, changing CDMOs requires a supplemental Manufacturing Change Supplement, averaging 18–24 months plus several million dollars of validation cost. That is why a CDMO that wins a commercial contract has very low customer churn and 10–15 year contract duration. This is Lonza's deepest moat and the least dependent on capital.
  • Large-scale capacity duopoly: the global players capable of mammalian biologics production with single stainless-steel reactors above 200,000 L are limited to Lonza, Samsung Biologics, Boehringer Ingelheim (mainly captive), Fujifilm, and a few others. Building such a plant requires USD 2 B+ of capital, 5–7 years, and FDA pre-approval inspection, creating very high capital and time barriers.
  • Scarce ADC process capability: ADCs involve a three-component complex process of highly potent payload + antibody + conjugation chemistry. Only 3–4 companies globally can do commercial production, and Lonza's Visp site is one of the largest bases.

  Over the next three to five years, the widening forces:

  • The BIOSECURE Act has become a policy tailwind: the BIOSECURE Act was signed into law on December 18, 2025 as part of the FY2026 National Defense Authorization Act, restricting US biotech cooperation with "entities of concern." The report framing needs an honest correction: unlike the 2024 draft, the final enacted law does not name WuXi in the statutory text. WuXi has not yet been designated as a restricted entity, and OMB must publish the list by December 2026. So the direction of "US customers shifting to Lonza" is valid, and Lonza's North America growth in 2025 was indeed above the group average, but the certainty is one notch softer than the report assumes.
  • Capacity scarcity persists: large-scale mammalian capacity is still a "seller's market" for the next 5–10 years.

  The narrowing force that must be confronted:

  • Samsung Biologics is expanding at close range: Samsung Biologics' 2025 revenue was KRW 4.56 T (roughly comparable in scale to Lonza's pure CDMO business), with an operating margin of about 45%. Its five Songdo plants total 785,000 L, the world's largest single biologics site; Plant 5 came online in April 2025 and starts contributing revenue in 2026. A competitor's 45% operating margin is far above Lonza's 2025 Core EBITDA margin of 31.6%, suggesting Samsung's cost curve/pricing power in scaled manufacturing has at times been stronger. Duopoly pricing power is not Lonza's alone.

  The Baillie Gifford takeaway: The "direction of moat width" is one of the dimensions Baillie Gifford values most. Lonza's moat is real, quantifiable, and has near-term policy tailwinds, so the direction tilts wider. But it is a strong company in a narrow club: the moat protects existing BLA projects and large-scale capacity, not against a cooling of new therapy categories, and Samsung is a similarly scaled, higher-margin rival competing at close range. This merits an upper-middle score for "solid moat, recently widening," but the "unassailable" premium must be removed. Lonza is the number two in a duopoly, not a monopolist.

  Jun 10, 2026
• QIf its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Conclusion first: over the past three years, Lonza has proved through a "forced reinvention" that it does have reinvention DNA. It proactively disposed of two non-core businesses, acquired large-scale capacity, changed CEO, and reset strategy, turning the fading of a single blockbuster (Moderna) into a structural upgrade toward "less single-customer dependence and a pure CDMO focus." Its way of handling bad news is to state it explicitly in financial reports, take one-off impairments, and write the lesson into baseline assumptions. That is relatively candid. This is one of its brighter answers in this framework.

  Start with a real case of "core business disruption": the mRNA fade. In 2020–2022, Lonza's largest single engine was manufacturing mRNA vaccines for Moderna, with peak annual revenue from a single customer of about CHF 1.5 B (about 25% of the group). After contract renegotiation in 2023–2024, it plunged to a steady state of about CHF 300–400 M. That is essentially the halving of a core growth engine. It is a real stress test of "reinvention DNA," not a hypothetical.

  Reinvention moves, proactive and systematic rather than passive:

  • CEO change + strategic reset: in April 2024, Wolfgang Wienand became CEO and narrowed the "broad integrated CDMO" approach into three core lanes: large-scale mammalian, ADC, and CGT, launching the "One Lonza" strategy.
  • Subtraction: in 2024, Lonza completed the disposal of Specialty Ingredients to Bain Capital at an enterprise value of about CHF 4.2 B; more aggressively, in March 2026 it announced the sale of CHI, about 30% of the former group's business, to Lone Star for EV CHF 2.3 B while retaining a 40% stake, completing the shift to a pure biologics CDMO via this transaction. Selling large chunks of itself twice in a row to focus shows real willingness to perform surgery. The report text still treats CHI as a business in hand, which is outdated.
  • Addition: in 2024 it acquired Roche's Vacaville site for USD 1.2 B (330,000 L), doubling large-scale capacity and using a "new lane taking over" to offset the mRNA fade.

  How it handles mistakes and bad news: relatively candidly.

  • The 2024 financial report explicitly listed the loss of Moderna business as an impact of about -CHF 1.1 B and explained why reported growth was far below core growth. It did not hide it.
  • Reported net profit in 2025 was a -CHF 275 M net loss. The company did not dress it up; it booked the Specialty Ingredients disposal loss and integration one-off costs, while also disclosing core net profit excluding one-offs, giving investors a "look-through" view.
  • Management wrote "growth without Moderna" directly into the 2028 baseline assumptions. It acknowledged that the old growth source could not be replicated and restarted from a more conservative base. That is bad news internalized as discipline.

  The honest limitation: this reinvention was largely "forced by the market" (the mRNA ebb plus a valuation retreat from the CHF 800 peak), not proactive self-reflection without external pressure. It also relies on capital actions such as selling businesses, buying capacity, and changing CEO, rather than a technical or cultural rebirth. Its regenerative capacity comes from "distributed capture of the R&D pipeline" (any new therapy breakout can take over), not from a uniquely antifragile organizational gene.

  The Baillie Gifford takeaway: Baillie Gifford puts special weight on whether a company can repair itself in adversity and face bad news honestly. Lonza scores upper-middle on this dimension: there was a real disruptive event, a systematic and decisive reinvention program, and candid booking of losses into the baseline. It gets a relatively high score, but because reinvention was more "forced + capital-allocation-led" than "proactive + organizationally transformative," some of the "great-company resilience" premium is withheld.

  Jun 10, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profits for the next five to ten years?5/10

  A

  Conclusion first: management has a long-term view, KPIs are deeply tied to margins, and it is willing to trade short-term accounting pain for long-term structure in order to focus. But this is a century-old company governed by professional managers, not a founder-controlled Baillie Gifford archetype where personal wealth is deeply tied to the share price. "Interest alignment" mainly comes through compensation incentives, not founder ownership. This is a structural weakness in this question.

  Governance and personnel background:

  • The CEO is an externally recruited professional manager: Wolfgang Wienand, formerly CEO of Siegfried Holding, took over in April 2024 and completed a strategic reset within one year. He is an industry veteran with strong execution, but he does not have founder-style personal wealth all-in. His incentives come from the compensation package and KPIs tied to margins/FCF.
  • There is no dominant founder control: Lonza was founded in 1897 and spun off independently in 1999. Ownership is highly dispersed, and the board chair is long-serving Albert Baehny (a senior director, not an owner in the sense of a controlling founding family). This is far from Baillie Gifford's preferred template of "founder heavily invested and operating with a decades-long view."

  Positive evidence of long-term thinking, based on actions rather than slogans:

  • Willingness to sacrifice current reporting optics for focus: Lonza made two major subtractions in a row: the 2024 disposal of Specialty Ingredients (EV about CHF 4.2 B), then the March 2026 sale of CHI, about 30% of the former group's revenue, to Lone Star for EV CHF 2.3 B, turning Lonza into a pure CDMO. Selling 30% of revenue to make the story purer and the moat more concentrated means near-term shrinkage but long-term quality improvement. It is a classic case of "sacrificing current scale for the next five to ten years."
  • Paying a high price for a long-tail annuity: in 2024 it acquired Roche's Vacaville site for USD 1.2 B (330,000 L), locking in a 10–15 year commercial outsourcing annuity. Using current capital and leverage to buy distant cash flows requires a long-term view.
  • Incentives are tied tightly to quality metrics: 2026 guidance explicitly targets a Core EBITDA margin above 32%, and management compensation is linked to structural KPIs such as margin and FCF rather than simply pushing revenue scale. That reduces agency risk from "destroying value for growth."

  Is it willing to sacrifice current profits for the long term? Partly, and with restraint. Lonza is willing to sacrifice "scale and current accounting profit" for focus, through business sales and one-off impairment charges that led to a reported net loss of -CHF 275 M in 2025. At the same time, it explicitly promises "continued margin expansion." The essence is "subtract to improve quality," not "accept indefinite losses for growth." This is prudent long-termism, not a moonshot-style spend-at-any-cost approach.

  The honest limitation, and the main deduction here: it lacks founder-style "captain and ship sharing the same fate." Professional management plus dispersed ownership means alignment comes from systems rather than personal net worth. CEO tenure and strategic continuity carry replacement risk. The "firmness" of the long-term view is weaker than in founder-controlled companies. The report also does not disclose management's personal shareholding ratio, so there is no evidence of deep financial alignment.

  The Baillie Gifford takeaway: Baillie Gifford treats "founder-style long-termism + deep alignment" as central to identifying great growth stocks. Lonza is above average on "long-term view + willingness to sacrifice the present for focus + quality-linked KPIs," but clearly weak on the subfactor Baillie Gifford values most: founder ownership and deep personal-company co-destiny. It earns a middle score. This is long-termism driven by good governance mechanisms rather than founder spirit: reliable, but missing the owner-operator soul Baillie Gifford loves most.

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulation?6/10

  A

  Conclusion first: if Lonza disappeared tomorrow, customers that already have drug processes written into FDA approval files would "miss it intensely." In the short term there is almost no like-for-like replacement, and supply interruption would directly threaten medicine availability. That is very strong indispensability. At the same time, its growth model is highly sustainable and does not rely on harming society or regulatory arbitrage; it sits on the same side as regulation by helping make medicines safely and compliantly. This is Lonza's strongest answer among the Baillie Gifford ten questions.

  Indispensability, quantified through switching costs:

  • Once a biologic's production process, manufacturing site, and raw-material supply chain are written into FDA BLA/NDA approval files, they are effectively frozen. Any change, including changing CDMO, requires a supplemental Manufacturing Change Supplement, averaging 18–24 months plus several million dollars in validation costs. For a blockbuster drug already on sale, Lonza disappearing suddenly would mean 1–2 years with no compliant alternative capacity, and potential drug supply disruption. That would be disastrous for patients and customers. This is the root cause of extremely low CDMO churn and 10–15 year contract duration, and it is the hard measure of "how much it would be missed."
  • Large-scale mammalian capacity is even scarcer: only about 4 global players can handle above 200,000 L. Samsung Biologics' five Songdo plants total 785,000 L, the world's largest single site, while Lonza including Vacaville (330,000 L) ranks among the top two. Removing Lonza's capacity would immediately tighten global large-scale outsourcing supply and demand.
  • Its customer base is extremely broad: it serves the global top 20 pharmaceutical companies plus hundreds of biotech startups. "Distributed capture of the R&D pipeline" means it is shared infrastructure for the whole industry, making indispensability industry-level rather than single-point.

  Is the growth model sustainable and not harmful to society or regulation? It is clean, and aligned with regulation.

  • Value creation comes from real process capability: Lonza makes money by "making hard-to-produce large molecules safely, compliantly, and at scale." It relies on process know-how, FDA/EMA-certified capacity, and capital barriers. This is real value creation, not harm to consumers, regulatory evasion, or network dominance.
  • Regulation is its moat, not an arbitrage target: its core barrier is precisely "strict adherence to FDA approval." The stricter regulation becomes, the higher switching costs rise and the wider the moat gets. Lonza is a beneficiary of compliance; there is no sustainability concern from "growing by exploiting regulatory loopholes."
  • Policy tailwinds reinforce social legitimacy: the BIOSECURE Act was signed into law in December 2025, pushing the US to shift critical drug capacity toward geopolitically trusted suppliers. Lonza (Switzerland + US Vacaville) is a beneficiary. An honest caveat is needed: the final enacted law did not name WuXi, and the designation list is due from OMB by the end of 2026. So this is a tailwind, not a fully realized locked-in benefit. Directionally, however, "supply-chain security" is encouraged by society and regulators, not suppressed by them.

  The only sustainability variable to watch (not a social/regulatory risk, but a business risk): ADCs involve highly potent cytotoxins. If an industry-level clinical safety event occurs, downstream demand would be hit. That is a risk of the therapy itself, not an ethical or compliance flaw in Lonza's growth model.

  The Baillie Gifford takeaway: Baillie Gifford uses "how much customers would miss it if it disappeared tomorrow + whether growth is sustainable and not socially harmful" to identify companies that are truly indispensable and can be socially allowed to grow for a long time. Lonza is strong on both. BLA lock-in gives it industry-level indispensability, while its growth is built on compliance, safety, and supply-chain resilience, moving in the same direction as regulation. This question deserves a high score. It is the most defensible dimension of Lonza as a high-quality picks-and-shovels business.

  Jun 10, 2026
• QWhat are the unit economics of this business, including gross margin and incremental returns? Do they improve or deteriorate with scale? Where does the money it earns go?5/10

  A

  Conclusion first: the unit economics are quite high-quality. Gross margin rises as products move up the lifecycle, and incremental returns are attractive because BLA lock-in creates long-tail annuities. Unit economics improve as scale rises and capacity fills, releasing operating leverage. The 2025 Core EBITDA margin has already risen to 31.6%, far above the 27.3% in the report text. The money earned mainly goes to capacity expansion, repayment of acquisition leverage, and bolt-on M&A, a heavy-asset compounding model that recycles cash back into the moat.

  Important number corrections, because the report text is systematically too low and should be updated to primary sources:

  • Lonza's 2025 Core EBITDA was about CHF 2.06 B, with a Core EBITDA margin of 31.6%, up 1.4 percentage points year on year; sales were CHF 6.5 B, up 21.7% at constant exchange rates. The report text's "Core EBITDA CHF 1.78 B / margin 27.3%" is outdated and too low. The real profitability is one notch stronger than the report describes, which matters a lot for unit economics.
  • 2026 guidance: Core EBITDA margin rising further above 32%. The medium-term "One Lonza" target is higher still. Margins are moving upward, confirming that unit economics improve as scale increases.

  Gross-margin structure: it rises layer by layer through the product lifecycle, a funnel annuity:

  • Early R&D services: USD 1–5 M annual revenue per project, gross margin about 30–40%, low-profit customer acquisition and seeding;
  • Clinical batch production: USD 5–50 M annual revenue per project, gross margin about 35–45%;
  • Commercial production: USD 50–300 M annual revenue per project, gross margin about 40–50%, with 10–15 year contract duration.

  For the same customer, the average span from first R&D work to commercialization is 7–10 years, and cumulative revenue is 50–100 times the initial phase. That is the most attractive feature of CDMO unit economics: low-margin early acquisition, followed by high-margin long-tail harvesting. The lifetime value of an incremental customer far exceeds the initial input.

  Incremental returns and operating leverage: they improve as scale rises.

  • CDMO is a heavy-asset business, and property, plant and equipment accounts for about 45% of total assets. But once capacity is online, utilization moving from low levels to full capacity quickly dilutes fixed costs and amplifies margins. That is exactly the source of the 1.4pct margin improvement in 2025 and guidance for a continued rise above 32%. Compared with Samsung Biologics' roughly 45% operating margin, the full-utilization ceiling of this business is even higher, and Lonza still has room to climb.
  • Cash conversion is excellent: the report discloses free cash flow conversion of about 80% (Core EBITDA→FCF), above the industry average. ROIC is about 11% after goodwill impairment and about 13% excluding acquisition one-offs, respectable for a heavy-asset business.

  Where the money goes: back into the moat plus deleveraging.

  • Capacity expansion: the USD 1.2 B acquisition of Vacaville (330,000 L) doubled large-scale capacity, turning cash into annuity assets for the next 15 years.
  • Debt reduction: net debt is CHF 3.8 B including Vacaville financing, and net debt/EBITDA is about 2.1x. FCF is prioritized toward bringing leverage back to a comfortable zone.
  • Reinvestment + bolt-on: with CHF 1.7 B of pre-listing cash from the CHI disposal, the company explicitly said it would invest in organic growth opportunities and bolt-on acquisitions, continuing to concentrate capital allocation in the highest-moat, highest-margin pure CDMO business.

  The honest limitation: heavy assets mean growth requires continuous capital expenditure. Free cash flow will be absorbed for a long time by capacity investment and M&A. This is not an asset-light, high-ROIC compounding machine. ROIC of about 11–13% is respectable but not spectacular, and large goodwill from Vacaville creates tail impairment risk.

  The Baillie Gifford takeaway: Baillie Gifford looks at unit economics, incremental returns, scale effects, and where capital is allocated. Lonza is solidly above average here: gross margin rises through the lifecycle, long-tail annuity customer lifetime value is excellent, margins demonstrably improve with scale, and the real figures are better than the report states. The money earned is recycled back into the moat. It gets an upper-middle score, with deductions for heavy assets, only mid-teens ROIC, and growth's continued dependence on capital investment. High-quality, but not "money-printer" unit economics.

  Jun 10, 2026
• QWhat conditions must all hold for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today's share price?3/10

  A

  Conclusion first: a fivefold rise in ten years requires profit CAGR of about 17%/year for ten years plus no valuation compression. That is about 4–6 percentage points above the top of management's 11–13% medium-term guidance and requires multiple positives to stack together: BIOSECURE benefits, full utilization of Vacaville/new capacity, ADC upside, and margins reaching 35%+. It is realistic but optimistic, not the base case. Today's CHF 495 share price (forward PE about 27x) already prices in "steady double-digit growth" and leaves little margin of safety for overdelivery. The valuation is not cheap.

  Set the price anchor first: current share price is about CHF 495.30 (2026-06-09), market cap about CHF 34.6 B, TTM PE about 38x including one-off impairment, forward PE about 27.1x, 69.84 million shares, and 2025 reported net profit was a -CHF 275 M loss. Sell-side consensus is optimistic: 22 analysts rate it "Strong Buy," with a 12-month target price of about CHF 663 (implying about +34% upside, but that is one year and depends on continued earnings beats).

  The conditions that must all hold for a fivefold return in ten years, shown clearly for the hurdle:

  1. Profit compound growth of about 17%/year for ten consecutive years: fivefold≈17.4% annualized. If the valuation multiple is unchanged ten years from now, share-price return≈EPS growth, requiring Core EPS to compound at about 17% for ten years. But the company's own medium-term guidance is only 11–13%. Reaching 17% requires sustained, long-term outperformance above the top of its own guidance.
  2. Margins reach and sustain 35%+: the 2025 Core EBITDA margin was already 31.6%, and 2026 guidance is above 32%. To support 17% profit growth, margins need to move toward Samsung Biologics' roughly 45% level, at least clearing 35%+, with new capacity kept fully utilized and no price war.
  3. BIOSECURE benefits truly materialize: the act was signed into law in December 2025, but the enacted version does not name WuXi and the designation list is due from OMB by the end of 2026. Turning a "policy direction" into "sustained order transfers" requires time and execution. It is a condition, not a locked-in fact.
  4. Valuation does not compress: today's 27x forward PE is already high. A fivefold return in ten years requires the market still to award a similar multiple a decade from now. If growth slows and the multiple falls back to 20x, even severalfold profit growth would be significantly eaten away by valuation compression.
  5. No black swans: no industry-level ADC safety event, no price war triggered by Samsung's expansion, and no prolonged biotech financing winter.

  What expectations are embedded in today's share price? Forward PE of about 27x implies expected EPS growth of roughly 12–15% based on a growth-stock PEG backsolve. The market has already priced in "management's medium-term guidance being delivered on schedule + partial BIOSECURE benefits." That means buying at the current price earns the money from "guidance delivery." Earning a fivefold return requires sustained, large overdelivery versus guidance, and the current price offers little discount for that extra layer. The report's own valuation conclusion also confirms this: the current price is at the lower end of the "reasonable but conservative range," with a reasonable buy ceiling around CHF 480, only about 1% away from the current price, leaving almost no margin of safety.

  Are these conditions realistic? Each condition individually is not absurd: biologics outsourcing is a real long runway, capacity is genuinely scarce, and policy is genuinely favorable. But all five holding simultaneously and continuously for ten years is an optimistic "everything goes right" scenario, not a base case. A more likely base case is "2–3 times over ten years" (11–13% compound growth plus mild multiple compression), not fivefold.

  The Baillie Gifford takeaway: This is Baillie Gifford's central test: "what conditions are needed for fivefold upside, and what does today's price imply?" The honest conclusion is that Lonza is a high-quality double-digit compounder, but a fivefold return in ten years requires long-term outperformance above its own guidance plus no valuation collapse. The hurdle is high and the probability is medium-low. At the current 27x price, "steady growth" is already priced in, with little margin of safety for overdelivery. This earns a lower-middle score: the growth imagination is real but not extreme, and today's entry price has already pulled forward most of the certain upside, leaving a thin discount for "fivefold."

  Jun 10, 2026
• QWhy has the market not recognized all this yet? Does it not understand, look down on it, or not look far enough? What will become the "narrative inflection point"?3/10

  A

  Conclusion first: the market has basically understood Lonza. This is not an ignored obscure stock; it is a clearly visible high-quality asset covered by sell-side analysts with a "Strong Buy" consensus and already valued at 27x forward earnings. The real perception gap is narrow and concentrated in two "not looking far enough" areas: ① the pace at which US order-transfer benefits materialize after the BIOSECURE Act, and ② the discounting speed of the pure CDMO transformation plus margin acceleration (2025 margin has quietly risen to 31.6%). The narrative inflection point will be triggered by quarterly data confirming or falsifying these two points, not by the discovery of a secret nobody knew.

  First, break the assumption that "the market has not recognized it": this is a known asset, not an obscure one.

  • The current share price is about CHF 495.30, market cap about CHF 34.6 B, and forward PE about 27.1x, while 22 analysts rate it "Strong Buy" with a 12-month target price of about CHF 663. This is a large-cap stock that is well researched, has optimistic consensus, and already carries a high valuation. There is no "nobody understands it" valuation hollow. So this question should not be forced into a "deeply undervalued hidden gem" narrative, which would overstate the case.

  So what perception gap remains? Mainly "not looking far enough," and not all of it necessarily favors Lonza:

  • The "soft certainty" of BIOSECURE benefits is misread by both sides: the report text assumes from the 2024 draft that "the act names WuXi and customers will inevitably shift to Lonza," which is too optimistic. But the market may also over-discount the benefit because the enacted law does not name WuXi and the designation list is due from OMB by the end of 2026. Reality sits in the middle: the direction is favorable, and 2025 North America growth was indeed above the group average, but timing is uncertain. Whoever first reads from quarterly data "how large and how fast the order shift really is" will capture that perception gap.
  • The pure CDMO transformation plus margin acceleration may be discounted with a lag: only in March 2026 did Lonza announce the sale of CHI to Lone Star for EV CHF 2.3 B and a full transition to pure CDMO, with closing in H2 2026, while the 2025 Core EBITDA margin had already risen to 31.6% and 2026 guidance is above 32%. After becoming a pure CDMO, the valuation anchor should move closer to Samsung Biologics' roughly 45% margin. The market may still be looking at it through the old frame of "integrated CDMO + one-off loss," and may be slow to discount "purification + quality uplift." That is a potential positive perception gap.

  What will become the narrative inflection point, including the implicit downside premises?

  • Positive inflection points: 2–3 consecutive quarters of North America/ADC revenue beating guidance → confirms that BIOSECURE order transfer is a real benefit; completion of the CHI disposal and pure CDMO margin confirmed above 32%+ → triggers a re-rating "toward Samsung"; EPS turning positive after one-offs, shifting the market from "TTM loss" to "core earnings."
  • Negative inflection points (must also be listed; YMYL cannot present only the bull case): Samsung Plant 5 reaching full capacity and triggering a price war that suppresses duopoly pricing power; OMB still not naming WuXi, falsifying the benefit; an industry-level ADC safety event; or a quarter missing margin/revenue guidance → the high 27x multiple could quickly compress back to 22–24x.

  Why this is "not looking far enough" rather than "not understanding" or "looking down on it": the market has long understood Lonza's business model: BLA lock-in, funnel annuities, and duopoly capacity. Nobody looks down on its scale and position either. The remaining disagreement is entirely about "how fast the next 1–3 years of policy benefit and quality uplift will be discounted." This is a time-horizon perception gap that needs future data to converge, not a gap in analytical sophistication.

  The Baillie Gifford takeaway: When Baillie Gifford asks "why has the market not recognized it," the purpose is to find underestimated non-consensus value. The honest conclusion is that Lonza's non-consensus is narrow. It is a fully priced known asset, with limited "not looking far enough" space only around BIOSECURE realization pace and pure CDMO quality-uplift discounting. That gap must be confirmed by quarterly data, and risk is symmetric because it may also be falsified. This earns a middle score: there is a real but small perception gap, and narrative inflection points are identifiable, but there is no thick safety cushion from "hidden value the market has badly misunderstood."

  Jun 10, 2026